JP5784626B2 - 免疫療法および抗腫瘍治療のための新規な結合体および組成物 - Google Patents

免疫療法および抗腫瘍治療のための新規な結合体および組成物 Download PDF

Info

Publication number
JP5784626B2
JP5784626B2 JP2012542587A JP2012542587A JP5784626B2 JP 5784626 B2 JP5784626 B2 JP 5784626B2 JP 2012542587 A JP2012542587 A JP 2012542587A JP 2012542587 A JP2012542587 A JP 2012542587A JP 5784626 B2 JP5784626 B2 JP 5784626B2
Authority
JP
Japan
Prior art keywords
component
cells
fusion protein
hil15
apoa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012542587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513377A5 (https=
JP2013513377A (ja
Inventor
ペドロ、ベラオンド、ロペス
ジェシカ、フィオラバンティ
ホセ、メディナ、エチェベルス
イグナシオ、ハビエル、メレロ、ベルメホ
マリア、デル、カルメン、オチョア、ニエト
フランシスコ、デ、アシス、パラソン、ガルシア
シルビア、ブルフォネ‐パウス
エルビン、ハンス、デュイトマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Proyecto de Biomedicina CIMA SL
Original Assignee
Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed by Forschungszentrum Borstel Leibniz Lungenzentrum FZB, Proyecto de Biomedicina CIMA SL filed Critical Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Publication of JP2013513377A publication Critical patent/JP2013513377A/ja
Publication of JP2013513377A5 publication Critical patent/JP2013513377A5/ja
Application granted granted Critical
Publication of JP5784626B2 publication Critical patent/JP5784626B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012542587A 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物 Expired - Fee Related JP5784626B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ES201030813 2010-05-27
ESP201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (3)

Publication Number Publication Date
JP2013513377A JP2013513377A (ja) 2013-04-22
JP2013513377A5 JP2013513377A5 (https=) 2014-01-30
JP5784626B2 true JP5784626B2 (ja) 2015-09-24

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542587A Expired - Fee Related JP5784626B2 (ja) 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物

Country Status (11)

Country Link
US (1) US8771664B2 (https=)
EP (1) EP2511294B1 (https=)
JP (1) JP5784626B2 (https=)
CN (1) CN102753574B (https=)
AU (1) AU2010329805B2 (https=)
BR (1) BR112012013868A8 (https=)
CA (1) CA2783876C (https=)
ES (1) ES2463016T3 (https=)
MX (1) MX2012006691A (https=)
RU (1) RU2597989C2 (https=)
WO (1) WO2011070214A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US11401312B2 (en) * 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
WO2015054701A2 (en) * 2013-10-13 2015-04-16 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness & myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
PL3094351T3 (pl) * 2014-01-15 2022-06-27 Kadmon Corporation, Llc Środki immunomodulujące
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
EP3307783B1 (en) * 2015-06-10 2021-01-06 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2023064469A1 (en) * 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
WO2024036145A1 (en) * 2022-08-07 2024-02-15 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
CA2214649C (en) 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
BR0115257A (pt) 2000-11-10 2003-08-12 Proteopharma Aps Análogos de apolipoproteìna
US8097283B2 (en) 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP2049560B1 (en) 2006-07-13 2013-05-15 Novozymes Biopharma DK A/S Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds

Also Published As

Publication number Publication date
ES2463016T3 (es) 2014-05-27
WO2011070214A8 (es) 2011-09-29
WO2011070214A3 (es) 2011-08-04
AU2010329805B2 (en) 2016-07-14
BR112012013868A2 (pt) 2017-01-10
US8771664B2 (en) 2014-07-08
US20120244118A1 (en) 2012-09-27
AU2010329805A1 (en) 2012-07-05
RU2012129208A (ru) 2014-01-20
CA2783876C (en) 2018-04-03
WO2011070214A2 (es) 2011-06-16
MX2012006691A (es) 2013-02-26
JP2013513377A (ja) 2013-04-22
RU2597989C2 (ru) 2016-09-20
EP2511294B1 (en) 2014-02-26
BR112012013868A8 (pt) 2017-12-26
CN102753574A (zh) 2012-10-24
CN102753574B (zh) 2015-05-20
EP2511294A2 (en) 2012-10-17
CA2783876A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
JP5784626B2 (ja) 免疫療法および抗腫瘍治療のための新規な結合体および組成物
EP3307783B1 (en) Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
ES2315008T3 (es) Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno.
ES2268863T3 (es) Receptores quimericos.
ES2939112T3 (es) Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario
AU733719B2 (en) Improved vaccines
CN105848674A (zh) 将白细胞介素-10用于治疗疾病和病症的方法
AU2007216170A1 (en) Molecules and methods of using same for treating CCR5/CCR5 ligands associated diseases
KR20160016725A (ko) 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
MX2010012746A (es) Molecula adaptadora para la administracion de vectores de adenovirus.
WO2018162450A1 (en) New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP2374813A1 (en) Use of phenol-soluble modulins for vaccine development
ES2362062A1 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ES2348674T3 (es) Miembros de la familia del receptor similar a ig leucociteno modificado (lir) con afinidad incrementada para mhc clase i y sus usos en la modulaciã“n de la activaciã“n de cã‰lula t.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150626

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150722

R150 Certificate of patent or registration of utility model

Ref document number: 5784626

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees